RT Journal Article
SR Electronic
T1 Topotecan as a Continuous Infusion Over 14 Days in Recurrent Ovarian Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1267
OP 1270
VO 24
IS 2C
A1 DENSCHLAG, D.
A1 WATERMANN, D.
A1 HÖRIG, K.
A1 KISSEL, C.
A1 TEMPFER, C.
A1 GITSCH, G.
YR 2004
UL http://ar.iiarjournals.org/content/24/2C/1267.abstract
AB Objective: In recurrent ovarian cancer the topoisomerase-1 inhibitor topotecan shows activity after prior treatment with platinum and taxanes. Overall response rates of up to 38% in combination with an acceptable toxicity profile have been reported. We performed a pilot study to evaluate the therapeutic efficacy and toxicity profile of a low-dose continuous infusion protocol of topotecan. Patients and Methods: Twelve patients with recurrent ovarian cancer and a measurable lesion received a continuous infusion of topotecan (0.4mg/m2/d) over 14 days, repeated every 28 days. All patients had at least one prior platinum-containing regimen of chemotherapy (range 1-7). Responses were evaluated by ultrasound, computed tomography (CT) scans and/or magnetic resonance imaging (MRI). Results: A total of 57 (median 5, range 1-12) topotecan treatment cycles were administered. The overall response rate was 2/12 (17%). Four patients had stable disease (33%), among them two patients with platinum-refractory tumors. The median time to progression was 26 (range 20-100) weeks. No grade 3 or 4 hematological toxicities were observed. However, one patient developed a grade 2 allergy leading to discontinuation of topotecan. Conclusion: Treatment of recurrent ovarian cancer with low-dose continuous infusion of topotecan over 14 days demonstrated response rates comparable to other dosing schedules with minimal toxicity in a preliminary series of 12 patients. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved